| abstract |
Biomarkers, method and early diagnosis kit for cancer of the pancreas, in particular, of ductal adenocarcinoma of the pancreas (DACP) and biomarkers, method and kit or device to predict or prognosticate the response of an individual to combination treatment with a nucleoside analogue (preferably gemcitabine) and with a growth receptor factor (preferably erlotinib) in patients with ductal adenocarcinoma of the pancreas. |